We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Qiagen to Increase Safety of Blood Donations in Brazil

By LabMedica International staff writers
Posted on 09 Jun 2009
Qiagen (Frankfurt, Germany) has entered into an agreement to supply molecular sample and assay technologies for a new national, polymerase chain reaction (PCR)-based blood screening program for human immunodeficiency virus (HIV) and Hepatitis C (HCV) in Brazil. More...


The company will provide Bio-Manguinhos (Rio de Janeiro, Brazil), the main provider of vaccines and diagnostics to the Brazilian Ministry of Health, with molecular testing solutions, sample and assay technologies, instrumentation, operational know-how, and training. The agreement will run for five years and contains options for subsequent extensions.

Qiagen's extraction and testing components will be included in the screening kits and sold in a format featuring Bio-Manguinhos's name and branding. The kits will run on a high-throughput multiplex PCR platform, which allows processing of large numbers of samples and detecting multiple pathogens in a single run. The highly automated platform, which includes an advanced control system based on biosafe viruses developed by Bio-Manguinhos, been validated in the field.

Brazil's new national screening program is scheduled to start in 2010. Every year, five million blood donations are performed in Brazil (population--190 million), of which 70% are conducted by public blood banks. Approximately 0.1% and 0.3% of these donations are tested positive for HIV and HCV, respectively, using older, less sensitive serological methods. It is believed that the real percent of positives could be significantly higher.

Peer M. Schatz, CEO of Qiagen said, "We are proud to team up with the Brazilian authorities in a combined effort to significantly reduce the number of blood-borne transmissions of HIV and HCV and the resulting disease burden."

Bio-Manguinhos is one of the official laboratories of the Brazilian Ministry of Health. The unit supports disease prevention policies, epidemiologic programs, sanitation, and surveillance in the immunobiologic area.

Qiagen is a global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA, and proteins from biologic samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible.

Related Links:

Qiagen
Bio-Manguinhos
Ministry of Health, Brazil



Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Host Response Immunoassay Test
MeMed BV
New
Silver Member
Quality Control Material
Multichem ID-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: Researchers have developed the first ever test for early detection of multiple sclerosis (Photo courtesy of 123RF)

Blood Test Detects Multiple Sclerosis Risk Years Before Onset of Symptoms

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system that affects around 2.8 million people worldwide. Its development is linked to immunological processes triggered... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Pathology

view channel
Image: Micrograph showing the distribution of misfolded proteins in myeloma cells (Photo courtesy of Helmholtz Munich)

Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.